Price
CHART BY
Frequently asked questions
What is Evaxion Biotech A/S ADR's market capitalization?
The market capitalization of Evaxion Biotech A/S ADR is $25.60M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Evaxion Biotech A/S ADR?
Evaxion Biotech A/S ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.054. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Evaxion Biotech A/S ADR's stock?
Currently, 4 analysts cover Evaxion Biotech A/S ADR's stock, with a consensus target price of $11.25. Analyst ratings provide insights into the stock's expected performance.
What is Evaxion Biotech A/S ADR's revenue over the trailing twelve months?
Over the trailing twelve months, Evaxion Biotech A/S ADR reported a revenue of $7.46M.
How many employees does Evaxion Biotech A/S ADR have, and what sector and industry does it belong to?
Evaxion Biotech A/S ADR employs approximately 46 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Evaxion Biotech A/S ADR's shares?
The free float of Evaxion Biotech A/S ADR is 6.74M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $25.60M
- EPS (TTM)
- -$1.054
- Free Float
- 6.74M
- Revenue (TTM)
- $7.46M
Pricing
- 52W span
- $2.71$12.02
Analyst Ratings
The price target is $11.25 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
Evaxion AS engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
- Employees
- 46
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- EVAX
Fundamentals & EOD data from FactSet